Edesa Biotech, Inc.
About Edesa Biotech, Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2021
- $0
- Net income
- -$7.2M
- Total assets
- $13.5M
- Market cap
- $48.6M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$7.9M
- Income tax
- $800
- Net income
- -$7.2M
- EPS (basic)
- $-1.27
Balance sheet
- Total assets
- $13.5M
- Current assets
- $11.5M
- Total liabilities
- $1.1M
- Current liabilities
- $1.1M
- Shareholders’ equity
- $12.5M
Cash flow
- Operating cash flow
- -$7.3M
- Investing cash flow
- -$9.7M
- Financing cash flow
- $17.0M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $48.6M
- Shares outstanding
- 9.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 9, 2010
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $7.2M in FY2021.
- Trading 71% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Edesa Biotech, Inc..
Write a review
News about Edesa Biotech, Inc.
News & sentiment via Polygon.io
